Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterised by the loss of dopamine-producing neurons in the brain, resulting in motor disturbances such as tremors, rigidity, and slowed movement. Although current therapies can improve symptoms, many patients experience side effects and a gradual decline in treatment effectiveness over time. This study employs comprehensive in silico methods to evaluate the therapeutic potential of ursodeoxycholic acid (UDCA) and tauroursodeoxycholic acid (TUDCA), two bile acids with emerging neuroprotective properties. Molecular docking studies were conducted using AutoDock 1.5.7 software, and the ADMET properties of the compounds were assessed using SwissADME. Toxicity analyses of UDCA and TUDCA were performed using T.E.S.T 5.1.2 software. Molecular dynamics (MD) simulations of UDCA–protein complexes were carried out via the iMOD server and CABS-flex V 2.0. Molecular docking simulations revealed promising interactions between UDCA and TUDCA with Parkinson’s disease-associated proteins selected from the literature, including 1XQ8, 6CM4, 6RKB, and 4PYK. UDCA generally exhibited stronger binding affinities of −5.38, −8.99, −8.21, and −6.50 kcal/mol compared to TUDCA (−5.08, −7.07, −8.30, −5.94 kcal/mol), except in the case of MAO-B. Molecular dynamics simulations further supported the stability of the UDCA–protein complexes, with eigenvalues calculated as 3.97×10⁻⁷, 2.39×10⁻⁶, 1.59×10⁻⁵, and 9.02×10⁻⁵. Pharmacokinetic analyses indicated favourable properties for both UDCA and TUDCA, including high oral bioavailability and blood–brain barrier permeability. UDCA displayed slightly higher toxicity in aquatic organisms but exhibited comparable developmental and mutagenic risks to TUDCA. Collectively, these computational findings highlight the multi-target potential of UDCA and TUDCA in modulating neuroinflammatory processes, mitigating oxidative stress, and supporting mitochondrial integrity—mechanistic pathways central to PD pathogenesis.